A study conducted by researchers at UCLA Health Johnsson Comprehensive Cancer Center in Los Angeles, CA, MD Anderson Cancer Center in Houston, TX, and Sloan Kettering Cancer Center in New York found that a cancer vaccine candidate called ELI-002 2P elicited a strong immune response in patients with colorectal and pancreatic cancer.

The study, published earlier this month in Nature Medicine , included the results from the phase 1 AMPLIFY-201 trial, which evaluated the safety and efficacy of ELI-002 2P, a lymph node-directed vaccine targeting KRAS mutations. These types of mutations occur in approximately 25% of solid tumors, including 50% of colorectal cancers and 93% of pancreatic cancers.

The ELI-002 2P vaccine candidate, developed by Boston-based Elicio Therapeutics, uses an amphip

See Full Page